Japan-based FUJIFILM Corporation and National Center of Neurology and Psychiatry have announced positive study results of Fujifilm’s new artificial intelligent (AI) technology to predict whether patients with mild cognitive impairment (MCI) will progress to Alzheimer’s disease (AD) within two years. 

The AI Technology for AD Progression Prediction has an 88% accuracy rate, which was published on April 12 in npj Digital Medicine, a high quality Nature Portfolio journal. The AI Technology for AD Progression Prediction was developed by Fujifilm based on its advanced image recognition technologies and machine learning expertise.

Following the successful study results, Fujifilm and the National Center of Neurology and Psychiatry will further verify the technology, with the aim of applying it to a stratification of patients in clinical trials for treatment of AD.

Fujifilm used its advanced image recognition technologies accumulated in the fields of photography and healthcare, to establish an AI technology that predicts the progression from MCI to AD with a high accuracy, even with limited learning data. The AI Technology for AD Progression Prediction makes predictions using multimodal information such as MRI images and cognitive test scores.